∙ Patients meeting all of the following inclusion criteria can be included in this trial:

• Age ≥ 18 years old;

• According to the World Health Organization (WHO) classification, subjects diagnosed with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) should meet one of the following criteria:

‣ Difficult to treat or recurrent (\>5% of primitive cells reappear in the bone marrow after complete remission) AML; (Single drug group)

⁃ Newly diagnosed AML subjects recognized by researchers as unable to receive standard treatment due to age, physical condition, or risk factors; (Joint group)

• MDS subjects belong to the following prognostic risk categories according to the revised International Prognostic Scoring System (IPSS-R):

‣ Extremely high-risk (\>6 points)

⁃ High risk (\>4.5 points - ≤ 6 points)

⁃ Medium risk (\>3 points - ≤ 4.5 points)

• Clearly indicating the presence of IDH2 gene mutation;

• Blood platelet (PLT) ≥20×10\^9/L； Or subjects with PLT\<20 × 10\^9/L, but recognized by the researchers as being caused by tumor reasons;

• Serum total bilirubin ≤ 1.5 × ULN (for Gilbert syndrome subjects, bilirubin ≤ 3 × ULN);

• Renal function: serum creatinine ≤ 1.5 × ULN or creatinine clearance rate ≥ 50ml/min;

• Recovery of toxic reactions caused by surgery, radiation therapy, or other anti-tumor treatments to ≤ Grade I;

• Women should agree to use contraceptive measures during the study period and within 6 months after the end of the study; Male participants must agree to use contraception during the study period and within 6 months after the end of the study period;

• The subjects voluntarily joined this study.